Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access
DOI: https://doi.org/10.2147/jpr.s457982
IF: 2.8319
2024-06-06
Journal of Pain Research
Abstract:Lynn Webster, 1 Jeffrey Gudin 2 1 Dr. Vince Clinical Research, Overland Park, KS, USA; 2 Department of Anesthesiology and Pain Management, University of Miami, Miller School of Medicine, Miami, FL, USA Correspondence: Lynn Webster, Dr. Vince Clinical Research, 1285 3rd Avenue, Salt Lake City, UT, 84103, USA, Tel +1 801-560-1707, Email The misuse and abuse of opioid analgesics continue to pose a serious public health concern, but for some patients, opioids remain an important analgesic option. Extended-release (ER) opioid formulations are effective for treating chronic pain and are supported by multiple 12-week efficacy studies. ER opioids often contain a high opioid content, and similar to immediate-release (IR) formulations, are subject to abuse, misuse, and diversion. Unintentional misuse may also occur when ER formulations are manipulated for medicinal administration, such as crushing a dose for easier oral intake. As part of a multipronged strategy designed to fight the opioid epidemic, abuse-deterrent formulations (ADFs) were developed to deter misuse, abuse, and diversion of opioids by making manipulation more difficult and nonoral routes of administration less rewarding. Although ADF opioids have been shown to decrease rates of abuse and diversion, they are not equally effective in terms of deterring manipulation for abuse or misuse. Xtampza ER utilizes DETERx technology, which allows it to retain ER characteristics when chewed or crushed, making it the only ER opioid without a boxed warning against these types of manipulation. OxyContin was also developed as an ADF but uses RESISTEC technology, making the tablet hard to crush and viscous in aqueous solutions. ADF utilization has been hampered by patient access issues, including high prices due to lack of insurance coverage. Postmarket real-world studies demonstrate lower rates of abuse, misuse, and diversion for ADF ER opioids compared with non-ADF formulations. However, similar studies comparing abuse-related effectiveness and health care costs for ADF opioids are warranted if clinicians are expected to utilize these potentially safer opioid formulations. These studies would support further education surrounding the benefits and utilization of ADFs and manipulation potential of different ADFs. Keywords: opioid analgesics, opioid crisis, chronic pain, tamper, abuse-deterrent, extended release Pain and chronic pain (lasting >3 months) are unpleasant sensory and emotional experiences associated with or resembling those associated with potential or actual tissue damage, which are highly debilitating and affect the quality of life of many adults in the US. 1–3 In 2021, an estimated 51.6 million adults in the US were affected by chronic pain and 17.1 million adults experienced high-impact chronic pain, defined as having pain every day or on most days during a 3-month period that substantially restricted participation in life or work activities. 2 Despite opioid misuse and abuse posing a serious and challenging public health problem, for a subset of patients with refractory pain, opioid analgesics remain an important component of pain management. 4 Common prescription opioids (limited to natural, semisynthetic, and methadone) were involved in 17,000 deaths (45 deaths per day) in the US in 2021. 5 Opioid use disorder (OUD) diagnoses and fatal overdoses increased dramatically during the COVID-19 pandemic. 6 A recent analysis by the Joint Economic Committee estimated that in 2020, the economic burden of illicit and licit opioid abuse and misuse reached almost $1.5 trillion. 7 A separate analysis considering the societal costs of OUD and opioid overdose deaths found that the greatest loss was the reduced quality of life from OUD and the value of life lost due to fatal opioid overdose. 8 These findings illustrate the magnitude of OUD as a persistent public health crisis and the devastating impact it has on individuals, families, and society. Support for opioid treatment has come under scrutiny despite therapeutic benefit. Regulatory agencies including the US Food and Drug Administration (FDA) encourage the development of abuse-deterrent formulations (ADF) as part of a multipronged approach for combating opioid misuse and abuse while ensuring that appropriate patients are treated effectively. The aim of this review is to discuss the properties of the available ADF products with evidence for abuse deterrence (eg, physical and chemical barriers) and how these properties may reduce abuse potential. The barriers that limit access to effective opioid treatment are also discussed. A trial of opioid therapy may be warranted if conservative and interventional analgesic treatments fail, and an individual's risk for OUD should be taken into considerat -Abstract Truncated-
clinical neurology